Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.